Cresco Labs FY2025 EPS Lowered by Alliance Global Partners

Key Points

• Alliance Global Partners has revised Cresco Labs' FY2025 earnings per share (EPS) estimate to (0.11), down from a previous forecast of (0.09), while the current consensus estimate is (0.20) EPS.
• Cresco Labs reported quarterly earnings of (0.05) EPS, missing analyst expectations by (0.01) and achieving revenues of $163.62 million, surpassing estimates.
• Canaccord Genuity Group downgraded Cresco Labs from a "strong-buy" to a "moderate buy" rating, although one analyst still rates it as a "Strong Buy" and another as "Hold."

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Investment analysts at Alliance Global Partners decreased their FY2025 earnings per share estimates for shares of Cresco Labs in a research note issued to investors on Wednesday, August 20th. Alliance Global Partners analyst A. Grey now anticipates that the company will earn ($0.11) per share for the year, down from their previous estimate of ($0.09). The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Cresco Labs' FY2026 earnings at ($0.04) EPS.

Separately, Canaccord Genuity Group downgraded Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a report on Tuesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy".

Cresco Labs Stock Up 6.8%

OTCMKTS CRLBF traded up $0.0845 during trading hours on Friday, hitting $1.32. The company had a trading volume of 1,417,772 shares, compared to its average volume of 801,483. Cresco Labs has a fifty-two week low of $0.4256 and a fifty-two week high of $1.8020. The company has a market capitalization of $648.14 million, a price-to-earnings ratio of -10.15 and a beta of 1.42. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.10 and a quick ratio of 2.22. The firm's 50 day moving average is $0.67 and its 200 day moving average is $0.71.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Cresco Labs had a negative net margin of 6.67% and a negative return on equity of 11.77%. The company had revenue of $163.62 million during the quarter, compared to analyst estimates of $162.00 million.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.